Compounding pharmacy shut down or lost 503A status for GLP-1s? A 2026 patient continuity guide: first 24-hour checklist, the four scenarios, what a warning letter actually means, three pharmacy-verification lookups, and how PlexusDx Semaglutide Injection ($179-$229/mo), Tirzepatide Injection ($229-$309/mo), Microdose GLP-1 Protocol ($129/mo), GLP-Squared ($179-$325/mo), and the Precision Peptide Genetic Test ($99 add-on) handle transfer patients.

The seven non-negotiable questions to ask before any GLP-1 telehealth consult, with green/yellow/red answer guides — pharmacy identity (503A vs 503B), compounded vs FDA-approved, total cost across month one through highest maintenance dose, escalation path, and the genetic-baseline question most cash-pay platforms skip.

503A vs 503B compounding pharmacy explained — the regulatory framework, FDA Modernization Act of 1997 and Drug Quality and Security Act of 2013, oversight differences, and a five-step verification checklist for compounded GLP-1 medications.

How to verify a 503A compounding pharmacy before ordering compounded semaglutide or tirzepatide: eight automatic walk-away triggers, a 10-minute audit using state-board, FDA, PCAB, and NABP databases, and where PlexusDx Weight Management Protocols sit in that framework.